CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: July 19, 2005
Result type: Reports
Project Number: SR0037-000
Product Line: Reimbursement Review

Generic Name: Erlotinib

Brand Name: Tarceva

Manufacturer: Hoffmann-La Roche Limited

Therapeutic Area: Cancer, Lung , non-small cell

Indications: Cancer, Lung , non-small cell

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: December 7, 2005

Recommendation Type: List with clinical criteria and/or conditions